Eli Lilly and - LLY Stock Forecast, Price & News

15 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Eli Lilly and in the last twelve months. There are currently 3 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" LLY shares.
View LLY analyst ratings or view top-rated stocks.

15 brokerages have issued 1 year price objectives for Eli Lilly and's stock. Their LLY share price forecasts range from $286.00 to $436.00. On average, they anticipate the company's stock price to reach $359.78 in the next twelve months. This suggests that the stock has a possible downside of 4.0%.
View analysts price targets for LLY or view top-rated stocks among Wall Street analysts.

Eli Lilly and's stock was trading at $276.22 on January 1st, 2022. Since then, LLY shares have increased by 35.7% and is now trading at $374.76.
View the best growth stocks for 2022 here.

Eli Lilly and saw a drop in short interest in November. As of November 15th, there was short interest totaling 5,610,000 shares, a drop of 8.0% from the October 31st total of 6,100,000 shares. Based on an average daily trading volume, of 3,000,000 shares, the short-interest ratio is currently 1.9 days. Currently, 0.7% of the shares of the stock are sold short.
View Eli Lilly and's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 2nd 2023.
View our LLY earnings forecast.

Eli Lilly and Company (NYSE:LLY) released its earnings results on Monday, October, 25th. The company reported $1.94 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.98 by $0.04. The firm earned $6.77 billion during the quarter, compared to analyst estimates of $6.64 billion. Eli Lilly and had a trailing twelve-month return on equity of 80.80% and a net margin of 20.63%. The firm's revenue for the quarter was up 18.0% compared to the same quarter last year. During the same quarter last year, the business earned $1.54 earnings per share.
Read the conference call transcript.

Eli Lilly and declared a quarterly dividend on Monday, October 17th. Stockholders of record on Tuesday, November 15th will be given a dividend of $0.98 per share on Friday, December 9th. This represents a $3.92 dividend on an annualized basis and a dividend yield of 1.05%. The ex-dividend date of this dividend is Monday, November 14th.
Read our dividend analysis for LLY.

Eli Lilly and (NYSE:LLY) pays an annual dividend of $3.92 per share and currently has a dividend yield of 1.06%. The company has been increasing its dividend for 8 consecutive years, indicating the company has a new, but growing committment to grow its dividend. The dividend payout ratio is 58.86%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, LLY will have a dividend payout ratio of 42.79% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for LLY.

Eli Lilly and declared that its board has authorized a stock buyback program on Monday, May 3rd 2021, which allows the company to buyback $5,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization allows the company to repurchase up to 2.8% of its stock through open market purchases. Stock buyback programs are typically a sign that the company's management believes its shares are undervalued.

Eli Lilly and issued an update on its FY 2022 earnings guidance on Tuesday, November, 8th. The company provided earnings per share guidance of $7.70-$7.85 for the period, compared to the consensus estimate of $7.99. The company issued revenue guidance of $28.50 billion-$29.00 billion, compared to the consensus revenue estimate of $28.85 billion.

399 employees have rated Eli Lilly and Chief Executive Officer David A. Ricks on Glassdoor.com. David A. Ricks has an approval rating of 86% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Eli Lilly and investors own include Johnson & Johnson (JNJ), Pfizer (PFE), NVIDIA (NVDA), Intel (INTC), Cisco Systems (CSCO), Bristol-Myers Squibb (BMY), Walt Disney (DIS), AT&T (T), Verizon Communications (VZ) and JPMorgan Chase & Co. (JPM).

Eli Lilly and trades on the New York Stock Exchange (NYSE) under the ticker symbol "LLY."

Eli Lilly and's stock is owned by a variety of retail and institutional investors. Top institutional investors include Lilly Endowment Inc. (10.92%), Vanguard Group Inc. (7.64%), State Street Corp (3.53%), Primecap Management Co. CA (2.95%), Price T Rowe Associates Inc. MD (2.61%) and Jennison Associates LLC (1.06%). Insiders that own company stock include Aarti S Shah, Acquisition Corp Kearny, Alfonso G Zulueta, Alonzo Weems, Donald A Zakrowski, Ilya Yuffa, Jackson P Tai, Lilly Endowment Inc, Marschall S Runge, Melissa S Barnes, Myles O'neill and Stephen F Fry.
View institutional ownership trends.

Shares of LLY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of LLY stock can currently be purchased for approximately $374.76.

Eli Lilly and (NYSE:LLY) has a market capitalization of $356.09 billion and generates $28.32 billion in revenue each year. The company earns $5.58 billion in net income (profit) each year or $6.66 on an earnings per share basis.

The company employs 35,000 workers across the globe.

Eli Lilly and's mailing address is LILLY CORPORATE CENTER, INDIANAPOLIS IN, 46285. The official website for the company is www.lilly.com. The company can be reached via phone at (317) 276-2000, via email at johnson_philip_l@lilly.com, or via fax at 317-276-4878.